The National Pharmaceutical Pricing Authority (NPPA) considered an application from M/s G.S. Pharmbutor Private Limited seeking exemption from the provisions of the Drugs (Prices Control) Order, 2013 in respect of the formulation “Povidone Iodine Throat Spray 0.45% w/v”. The formulation was approved by the Office of Central Drugs Standard Control Organisation (India) as a new drug under the Drugs and Cosmetics Act, 1940 and the rules made thereunder. At its 150th meeting held on August 25, 2026, NPPA considered the recommendations of the Multidisciplinary Committee and approved the non-application of the provisions of DPCO, 2013 under paragraph 32(iii) for five years from the date of market approval in India.

M/s G.S. Pharmbutor Private Limited is exempted from the provisions of DPCO, 2013 under paragraph 32(iii) in respect of “Povidone Iodine Throat Spray 0.45% w/v” for five years with effect from December 17, 2024, being the date of grant of marketing approval by the Central Drugs Standard Control Organisation. The company shall inform NPPA of the Price to Retailer (PTR) and Maximum Retail Price (MRP) fixed by it for the formulation by issuing a price list in Form V under DPCO, 2013. The company shall also seek retail price approval for the formulation, as applicable, three months before expiry of the exemption granted under paragraph 32(iii) of DPCO, 2013.